AGN-199201

DRUG2 trials

Sponsors

Allergan

Conditions

ErythemaPresbyopiaRosacea

Phase 2

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

CompletedNCT02197806

AllerganPresbyopia

Start: 2014-07-31End: 2014-11-30Updated: 2015-12-03

Phase 3

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

CompletedNCT02131636

AllerganErythema, Rosacea

Start: 2014-05-31End: 2014-12-31Updated: 2019-11-18